{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:06:00Z","timestamp":1791576360927,"version":"4.3.4"},"reference-count":39,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2014.00233","type":"journal-article","created":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T07:05:59Z","timestamp":1400742359000},"source":"Crossref","is-referenced-by-count":38,"title":["Characterization of Novel PI3K\u00ce\u00b4 Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies"],"prefix":"10.3389","volume":"5","author":[{"given":"Philipp","family":"Haselmayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Muzerelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"El Bawab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Waltzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Abla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Polokoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Jond-Necand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maril\u00c3\u00a8ne","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bertschy Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Gretener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Stella","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Grenningloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ladel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00c3\u00b8rgen S\u00c3\u00b8berg","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/0961203309358187","article-title":"Review: lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions","volume":"19","author":"Ortega","year":"2010","journal-title":"Lupus"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.clinthera.2012.02.028","article-title":"Belimumab: review of use in systemic lupus erythematosus","volume":"34","author":"Boyce","year":"2012","journal-title":"Clin Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1146\/annurev.biochem.70.1.535","article-title":"Synthesis and function of 3-phosphorylated inositol lipids","volume":"70","author":"Vanhaesebroeck","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.pharmthera.2008.02.004","article-title":"Taming the PI3K team to hold inflammation and cancer at bay","volume":"118","author":"Hirsch","year":"2008","journal-title":"Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/82_2010_45","article-title":"PI3Ks in lymphocyte signaling and development","volume":"346","author":"Okkenhaug","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1084\/jem.20070763","article-title":"PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation","volume":"205","author":"Guiducci","year":"2008","journal-title":"J Exp Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.4049\/jimmunol.1101602","article-title":"Enhanced phosphoinositide 3-kinase delta activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death","volume":"187","author":"Suarez-Fueyo","year":"2011","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jaut.2012.04.001","article-title":"Attenuation of phosphoinositide 3-kinase delta signaling restrains autoimmune disease","volume":"38","author":"Maxwell","year":"2012","journal-title":"J Autoimmun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nm1284","article-title":"Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis","volume":"11","author":"Camps","year":"2005","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.vascn.2009.10.001","article-title":"Chemical target and pathway toxicity mechanisms defined in primary human cell systems","volume":"61","author":"Berg","year":"2010","journal-title":"J Pharmacol Toxicol Methods"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1177\/1087057113505324","article-title":"Building predictive models for mechanism-of-action classification from phenotypic assay data sets","volume":"18","author":"Berg","year":"2013","journal-title":"J Biomol Screen"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e58966","DOI":"10.1371\/journal.pone.0058966","article-title":"Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation","volume":"8","author":"Melton","year":"2013","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1089\/adt.2004.2.431","article-title":"Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models","volume":"2","author":"Kunkel","year":"2004","journal-title":"Assay Drug Dev Technol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1096\/fj.04-1538fje","article-title":"An integrative biology approach for analysis of drug action in models of human vascular inflammation","volume":"18","author":"Kunkel","year":"2004","journal-title":"FASEB J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys","volume":"181","author":"Crispin","year":"2008","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"B20","first-page":"12","article-title":"Relevance of systemic lupus erythematosus nephritis animal models to human disease","volume":"19","author":"Foster","year":"1999","journal-title":"Semin Nephrol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/eji.201040649","article-title":"Interferon-alpha induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZBxNZW)F1 mice but not in BALB\/c mice","volume":"41","author":"Mathian","year":"2011","journal-title":"Eur J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/08916930310001605873","article-title":"Induction of clinical autoimmune disease by therapeutic interferon-alpha","volume":"36","author":"Gota","year":"2003","journal-title":"Autoimmunity"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.4049\/jimmunol.1004142","article-title":"IFN-alpha confers resistance of systemic lupus erythematosus nephritis to therapy in NZB\/W F1 mice","volume":"187","author":"Liu","year":"2011","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.04031.x","article-title":"Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis","volume":"159","author":"Wang","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/ni.1741","article-title":"Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus","volume":"10","author":"Doreau","year":"2009","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ni1552","article-title":"Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice","volume":"9","author":"Hsu","year":"2008","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"R62","DOI":"10.1186\/ar4499","article-title":"T helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?","volume":"16","author":"Brkic","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJM199805073381906","article-title":"Antibodies to DNA","volume":"338","author":"Hahn","year":"1998","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/icb.2012.10","article-title":"Role of type I interferons in the activation of autoreactive B cells","volume":"90","author":"Kiefer","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.4049\/jimmunol.176.4.2074","article-title":"Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN","volume":"176","author":"Le","year":"2006","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.it.2005.09.001","article-title":"SLE: challenges and candidates in human disease","volume":"26","author":"Croker","year":"2005","journal-title":"Trends Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation","volume":"196","author":"Clayton","year":"2002","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1002\/art.38119","article-title":"The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus","volume":"65","author":"Golding","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B35","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.autrev.2011.05.004","article-title":"Human FoxP3+ regulatory T cells in systemic autoimmune diseases","volume":"10","author":"Miyara","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Patton","year":"2006","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.drudis.2013.05.001","article-title":"The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives","volume":"18","author":"Bueters","year":"2013","journal-title":"Drug Discov Today"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-014-9818-0","article-title":"Inhibition of PI3Kdelta improves systemic lupus in mice","author":"Wang","year":"2014","journal-title":"Inflammation"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T20:27:44Z","timestamp":1424291264000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2014.00233\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,22]]},"references-count":39,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2014.00233","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,22]]}}}